Regeneron Pharmaceuticals is trading at $928.66, up 12.58%, after third-quarter 2026 revenue and non-GAAP EPS beat analyst expectations. - Revenue was $5.12 billion, up 36% year over year; non-GAAP EPS was $20.07, up 70%. - The company raised expected 2026 non-GAAP gross margin to approximately 86% and expanded its Sanofi collaboration with a $1.0 billion upfront payment. - These results and updates provided a clear company-specific catalyst for the October 30 gain.